New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Researchers suggest air pollution be included as risk factor for patients with lung cancer and have never smoked

Researchers suggest air pollution be included as risk factor for patients with lung cancer and have never smoked

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainResearchers from Vancouver, British Columbia examine the effect of duration of past exposure to air pollution
World medicine December 15,2023
Researchers suggest air pollution be included as risk factor for patients with lung cancer and have never smoked

Researchers suggest air pollution be included as risk factor for patients with lung cancer and have never smoked

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainResearchers from Vancouver, British Columbia examine the effect of duration of past exposure to air pollution
World medicine December 15,2023
Study finds second primary lung cancer is 4 percent and as high as 8 percent among surgery patients

Study finds second primary lung cancer is 4 percent and as high as 8 percent among surgery patients

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainUsing data from the National Lung Screening Trial, researchers found that the incidence of second primary lung
World medicine December 15,2023
Study finds second primary lung cancer is 4 percent and as high as 8 percent among surgery patients

Study finds second primary lung cancer is 4 percent and as high as 8 percent among surgery patients

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainUsing data from the National Lung Screening Trial, researchers found that the incidence of second primary lung
World medicine December 15,2023
CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

byDana-Farber Cancer InstituteAn artist’s depiction of a T cell. Credit: NIAIDA CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a
World medicine December 15,2023
CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial

byDana-Farber Cancer InstituteAn artist’s depiction of a T cell. Credit: NIAIDA CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a
World medicine December 15,2023
Stopping moles from turning into the deadliest type of skin cancer

Stopping moles from turning into the deadliest type of skin cancer

byBoston UniversityBRAFV600Eactivates the Hippo tumor-suppressor pathway. a Representative immunoblot (IB) of dox-inducible BRAFV600EMel-ST cells cultured ± dox for 24 h. b IB of two
World medicine December 15,2023
Stopping moles from turning into the deadliest type of skin cancer

Stopping moles from turning into the deadliest type of skin cancer

byBoston UniversityBRAFV600Eactivates the Hippo tumor-suppressor pathway. a Representative immunoblot (IB) of dox-inducible BRAFV600EMel-ST cells cultured ± dox for 24 h. b IB of two
World medicine December 15,2023
Sugar chains on cell surfaces direct cancer cells to die

Sugar chains on cell surfaces direct cancer cells to die

by Toho UniversityCancer cells highly expressing Lewis glycans on glycolipids are vulnerable to the death-inducing cytokine, TRAIL. Measurement of Lewis glycans on cancer cells could be a better predi
World medicine December 15,2023
Sugar chains on cell surfaces direct cancer cells to die

Sugar chains on cell surfaces direct cancer cells to die

by Toho UniversityCancer cells highly expressing Lewis glycans on glycolipids are vulnerable to the death-inducing cytokine, TRAIL. Measurement of Lewis glycans on cancer cells could be a better predi
World medicine December 15,2023
Tabrecta gains full FDA approval for non-small cell lung cancer

Tabrecta gains full FDA approval for non-small cell lung cancer

The U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a genetic mutation leadi
World medicine December 15,2023
Tabrecta gains full FDA approval for non-small cell lung cancer

Tabrecta gains full FDA approval for non-small cell lung cancer

The U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a genetic mutation leadi
World medicine December 15,2023
Efficacy of durvalumab for early-stage triple-negative breast cancer examined by race

Efficacy of durvalumab for early-stage triple-negative breast cancer examined by race

Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for
World medicine December 15,2023
Efficacy of durvalumab for early-stage triple-negative breast cancer examined by race

Efficacy of durvalumab for early-stage triple-negative breast cancer examined by race

Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for
World medicine December 15,2023
Robotic kidney cancer surgery shows desirable outcomes in study

Robotic kidney cancer surgery shows desirable outcomes in study

byUniversity of Texas Health Science Center at San AntonioIn thisillustration, a mass (depicted as jagged) is shown on a kidney (Level I, at left). The tumor extends up the inferior vena c
World medicine December 15,2023
Robotic kidney cancer surgery shows desirable outcomes in study

Robotic kidney cancer surgery shows desirable outcomes in study

byUniversity of Texas Health Science Center at San AntonioIn thisillustration, a mass (depicted as jagged) is shown on a kidney (Level I, at left). The tumor extends up the inferior vena c
World medicine December 15,2023
New method mass-produces antitumor cells to treat blood diseases and cancer

New method mass-produces antitumor cells to treat blood diseases and cancer

by Steve Martin,Purdue UniversityXiaoping Bao, Purdue University assistant professor from the Davidson School of Chemical Engineering. Credit: Xiaoping BaoA Purdue University chemical engineer h
World medicine December 15,2023
New method mass-produces antitumor cells to treat blood diseases and cancer

New method mass-produces antitumor cells to treat blood diseases and cancer

by Steve Martin,Purdue UniversityXiaoping Bao, Purdue University assistant professor from the Davidson School of Chemical Engineering. Credit: Xiaoping BaoA Purdue University chemical engineer h
World medicine December 15,2023
Alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

Alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

by Impact JournalsRepresentative images of PD-L1 (A), CD8 (B) and mucin (C) and staining. Credit: Baretti et al.A new research paper was published inOncotargeton July 28, 2022, entitled, &
World medicine December 15,2023
Alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

Alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

by Impact JournalsRepresentative images of PD-L1 (A), CD8 (B) and mucin (C) and staining. Credit: Baretti et al.A new research paper was published inOncotargeton July 28, 2022, entitled, &
World medicine December 15,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com